Abbott Laboratories (ABT)

$106.89

-0.7

(-0.65%)▲

Market is closed - opens 7 PM, 25 Apr 2024
star icon

Abbott Laboratories is a global healthcare company that specializes in the discovery, development, and manufacturing of innovative medical devices and diagnostics.

Insights on Abbott Laboratories

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 10.24B → 9.96B (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.59B → 1.22B (in $), with an average decrease of 23.2% per quarter

  • Vs JNJ

    In the last 3 years, Abbott Laboratories has experienced a drawdown of -12.7%, however Johnson & Johnson resisted the overall trend and outperformed by 3.1%

Performance

  • $105.65
    $107.09
    $106.89
    downward going graph

    1.16%

    Downside

    Day's Volatility :1.34%

    Upside

    0.19%

    downward going graph
  • $88.80
    $121.04
    $106.89
    downward going graph

    16.92%

    Downside

    52 Weeks Volatility :26.64%

    Upside

    11.69%

    downward going graph

Returns

PeriodAbbott LaboratoriesSector (Health Care)S&P500
3 Months
-4.32%
2.0%
3.6%
6 Months
13.48%
11.7%
21.1%
1 Year
-2.16%
5.8%
24.5%
3 Years
-12.23%
14.2%
21.3%

Highlights

Market Capitalization
185.8B
Book Value
$22.26
Dividend Share
2.12
Dividend Yield
2.05%
Earnings Per Share (EPS)
3.21
PE Ratio
33.36
PEG Ratio
5.99
Wall Street Target Price
126.79
Profit Margin
13.96%
Operating Margin TTM
14.06%
Return On Assets TTM
6.11%
Return On Equity TTM
15.11%
Revenue TTM
40.3B
Revenue Per Share TTM
23.18
Quarterly Revenue Growth YOY
2.1999999999999997%
Gross Profit TTM
24.6B
EBITDA
10.3B
Diluted Eps TTM
3.21
Quarterly Earnings Growth YOY
-0.07
EPS Estimate Current Year
4.61
EPS Estimate Next Year
5.09
EPS Estimate Current Quarter
0.95
EPS Estimate Next Quarter
1.12

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 28 Wall street analysts offering stock ratings for Abbott Laboratories(by analysts ranked 0 to 5 stars)
Based on 28 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
21
21
Hold
7
7
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 18.62%

Current $106.89
Target $126.79

Company Financials

FY18Y/Y Change
Revenue
30.6B
↑ 11.64%
Net Income
2.4B
↑ 396.44%
Net Profit Margin
7.74%
↑ 6.0%
FY19Y/Y Change
Revenue
31.9B
↑ 4.34%
Net Income
3.7B
↑ 55.7%
Net Profit Margin
11.56%
↑ 3.82%
FY20Y/Y Change
Revenue
34.6B
↑ 8.48%
Net Income
4.5B
↑ 21.91%
Net Profit Margin
12.99%
↑ 1.43%
FY21Y/Y Change
Revenue
43.1B
↑ 24.47%
Net Income
7.1B
↑ 57.31%
Net Profit Margin
16.42%
↑ 3.43%
FY22Y/Y Change
Revenue
43.7B
↑ 1.34%
Net Income
6.9B
↓ 1.95%
Net Profit Margin
15.88%
↓ 0.54%
FY23Y/Y Change
Revenue
40.1B
↓ 8.12%
Net Income
5.7B
↓ 17.45%
Net Profit Margin
14.27%
↓ 1.61%
Q4 FY22Q/Q Change
Revenue
10.1B
↓ 3.06%
Net Income
1.0B
↓ 28.01%
Net Profit Margin
10.24%
↓ 3.54%
Q1 FY23Q/Q Change
Revenue
9.7B
↓ 3.41%
Net Income
1.3B
↑ 27.59%
Net Profit Margin
13.52%
↑ 3.28%
Q2 FY23Q/Q Change
Revenue
10.0B
↑ 2.37%
Net Income
1.4B
↑ 4.32%
Net Profit Margin
13.78%
↑ 0.26%
Q3 FY23Q/Q Change
Revenue
10.1B
↑ 1.65%
Net Income
1.4B
↑ 4.44%
Net Profit Margin
14.16%
↑ 0.38%
Q4 FY23Q/Q Change
Revenue
10.2B
↑ 0.97%
Net Income
1.6B
↑ 11.0%
Net Profit Margin
15.56%
↑ 1.4%
Q1 FY24Q/Q Change
Revenue
10.0B
↓ 2.7%
Net Income
1.2B
↓ 23.15%
Net Profit Margin
12.29%
↓ 3.27%
FY18Y/Y Change
Total Assets
67.2B
↓ 11.9%
Total Liabilities
36.5B
↓ 19.27%
FY19Y/Y Change
Total Assets
67.9B
↑ 1.06%
Total Liabilities
36.6B
↑ 0.37%
FY20Y/Y Change
Total Assets
72.5B
↑ 6.87%
Total Liabilities
39.5B
↑ 8.09%
FY21Y/Y Change
Total Assets
75.2B
↑ 3.65%
Total Liabilities
39.2B
↓ 0.94%
FY22Y/Y Change
Total Assets
74.4B
↓ 1.01%
Total Liabilities
37.5B
↓ 4.18%
FY23Y/Y Change
Total Assets
73.2B
↓ 1.64%
Total Liabilities
34.4B
↓ 8.38%
Q4 FY22Q/Q Change
Total Assets
74.4B
↑ 2.25%
Total Liabilities
37.5B
↑ 1.67%
Q1 FY23Q/Q Change
Total Assets
73.8B
↓ 0.87%
Total Liabilities
36.6B
↓ 2.59%
Q2 FY23Q/Q Change
Total Assets
73.4B
↓ 0.6%
Total Liabilities
36.0B
↓ 1.67%
Q3 FY23Q/Q Change
Total Assets
72.1B
↓ 1.72%
Total Liabilities
34.4B
↓ 4.32%
Q4 FY23Q/Q Change
Total Assets
73.2B
↑ 1.56%
Total Liabilities
34.4B
↓ 0.03%
FY18Y/Y Change
Operating Cash Flow
6.3B
↑ 13.11%
Investing Cash Flow
-1.4B
↓ 85.9%
Financing Cash Flow
-10.4B
↑ 96.76%
FY19Y/Y Change
Operating Cash Flow
6.1B
↓ 2.6%
Investing Cash Flow
-1.8B
↑ 33.85%
Financing Cash Flow
-4.3B
↓ 58.72%
FY20Y/Y Change
Operating Cash Flow
7.9B
↑ 28.76%
Investing Cash Flow
-2.2B
↑ 22.04%
Financing Cash Flow
-2.8B
↓ 35.21%
FY21Y/Y Change
Operating Cash Flow
10.5B
↑ 33.31%
Investing Cash Flow
-2.0B
↓ 9.35%
Financing Cash Flow
-5.5B
↑ 97.7%
FY22Y/Y Change
Operating Cash Flow
9.6B
↓ 9.04%
Investing Cash Flow
-1.7B
↓ 13.35%
Financing Cash Flow
-7.6B
↑ 38.99%
Q3 FY22Q/Q Change
Operating Cash Flow
2.8B
↑ 15.35%
Investing Cash Flow
-1.1B
↑ 319.7%
Financing Cash Flow
-1.5B
↑ 89.79%
Q4 FY22Q/Q Change
Operating Cash Flow
2.3B
↓ 16.33%
Investing Cash Flow
-632.0M
↓ 42.96%
Financing Cash Flow
-1.5B
↓ 5.57%
Q1 FY23Q/Q Change
Operating Cash Flow
1.1B
↓ 50.86%
Investing Cash Flow
-462.0M
↓ 26.9%
Financing Cash Flow
-1.4B
↓ 3.23%
Q2 FY23Q/Q Change
Operating Cash Flow
1.2B
↑ 5.25%
Investing Cash Flow
-1.2B
↑ 162.55%
Financing Cash Flow
-1.3B
↓ 8.58%
Q3 FY23Q/Q Change
Operating Cash Flow
1.9B
↑ 56.03%
Investing Cash Flow
-634.0M
↓ 47.73%
Financing Cash Flow
-2.3B
↑ 81.54%

Technicals Summary

Sell

Neutral

Buy

Abbott Laboratories is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abbott Laboratories
Abbott Laboratories
-2.2%
13.48%
-2.16%
-12.23%
37.74%
Johnson & Johnson
Johnson & Johnson
-4.31%
-1.33%
-10.08%
-8.87%
6.36%
Pfizer Inc.
Pfizer Inc.
-4.05%
-13.51%
-34.05%
-31.95%
-33.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abbott Laboratories
Abbott Laboratories
33.36
33.36
5.99
4.61
0.15
0.06
0.02
22.26
Johnson & Johnson
Johnson & Johnson
20.07
20.07
0.89
10.66
0.18
0.08
0.03
28.57
Pfizer Inc.
Pfizer Inc.
70.97
70.97
0.26
2.21
0.02
0.02
0.06
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abbott Laboratories
Abbott Laboratories
Buy
$185.8B
37.74%
33.36
13.96%
Johnson & Johnson
Johnson & Johnson
Hold
$359.3B
6.36%
20.07
47.37%
Pfizer Inc.
Pfizer Inc.
Buy
$148.7B
-33.15%
70.97
3.62%

Institutional Holdings

  • Vanguard Group Inc

    9.02%

  • BlackRock Inc

    7.73%

  • Capital Research Global Investors

    4.99%

  • State Street Corporation

    4.30%

  • Capital Research & Mgmt Co - Division 3

    3.71%

  • Morgan Stanley - Brokerage Accounts

    2.07%

Corporate Announcements

  • Abbott Laboratories Dividends March,2024

    In the quarter ending March,2024. Abbott Laboratories has declared dividend of $0.55

    Read More

Company Information

Abbott Laboratories, headquartered in Chicago, Illinois, was founded in 1888 by a physician named Dr Wallace Calvin. His purpose was to improve people's well-being and help them reach their full potential at different stages of their lives. Founded as a drug formulation company, today, Abbott Laboratories is a worldwide leader in healthcare, medical devices, nutritional products, and pharmaceutical drugs. Even though it reached the shores of India a century ago, it is still regarded as one of the largest healthcare product companies. With a focus on cardiovascular, diagnostic, diabetes, and neuromodulation products, some of its popular brands include Pedialyte, Glucerna, Similac, Ensure, and iStat. Abbott opened its first international office in London in 1907, and currently operates in over 160 countries. Its growth is also a result of strategic acquisitions. Abbott’s recent acquisitions include Kalo Pharma International in 2014, which doubled its brand generic drug portfolio. It acquired Tendyne in 2015 and along with it the company’s minimally invasive mitral valve replacement therapies. Another gem in the crown is the acquisition of Alere in 2016, which gave Abbott access to the largest mail-order diabetic supplier, Arriva Medical. Along with strategic acquisitions, the company is dedicated to gaining a strong competitive advantage. With the onset of COVID-19, the company has developed various antibody tests that have been granted emergency-use authorization. According to Forbes, Abbott Laboratories' fast and low-cost testing methods have expedited the detection of COVID-19 virus. For its 2030 sustainability plan, the company is gearing up to introduce revolutionary products such as BinaxNOW, a COVID-19 test, and FreeStyle Libre, an innovative glucose monitoring device. Abbott’s future plans are centred around providing cutting-edge technologies at affordable prices to even the most vulnerable sections of society. Currently Abbott Laboratories has a market cap of $185.79 Billion. It has a P.E ratio of 32.46. The shares of Abbott Laboratories are trading at $107.59. .

Organization
Abbott Laboratories
Employees
114000
CEO
Mr. Robert B. Ford
Industry
Health Technology

Discover More

FAQs